Novelion Therapeutics (NVLN) Posts Q2 Loss of $0.08 on Revenue of $40.9M
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/13/2026
- Tech stocks power S&P 500 to record high as oil, producer inflation weaken
- Oil falls more than 3% on weaker global demand outlook and US crude buildup
- BofA lifts server CPU TAM to $210bn+ on the rise of AI agents
- Burry doubles down on Nebius short after stock surges 34% on earnings
- JPMorgan gets bullish on Salesforce, says concerns are "overblown"
- After-Hours Movers: CSCO, COHR, HLIT, CBRS, STUB, ENS
- After-Hours Movers: CRWV, NBIS, SMCI, LITE, CAVA, HRB
- After-Hours Movers: P, RIOT, BW, RKLB, HIMS, UPWK
- After-Hours Movers: TEAM, NET, TWLO, DOCS, FROG, DV, TTD, ABNB, DKNG, SG, RKT
- After-Hours Stock Movers: WDC, SNDK, FIG, APP, HUBS, SOUN, DASH, XYZ, Z, FLNC
Novelion Therapeutics Reports Second Quarter 2017 Financial Results
August 8, 2017 7:00 AM EDTMYALEPT® Total Net Revenues Increase 28% Over Prior Quarter, Excluding One-Time AdjustmentsGlobal Expansion Plans for Metreleptin Opportunity UnderwayCompany Updates Guidance for FY 2017 Total Net RevenuesConference call to be held today at 8:30 a.m. ET
VANCOUVER, Aug. 08, 2017 (GLOBE NEWSWIRE) -- Novelion Therapeutics Inc. (NASDAQ: NVLN), a biopharmaceutical company dedicated to developing and commercializing innovative new therapies for individuals living with rare and unmet need diseases (Novelion or the Company), today reported financial results for the second quarter ended June 30, 2017 and provided an overview of... More
